Chinese Cancer Prevention Study(CHICAPS)

Cervical Cancer Clinical Trial

— CHICAPS  

Official title:

Chinese Cancer Prevention Study(CHICAPS) Mass Population Based Cervical Cancer Screening

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01524003
• Other study ID #: CHICAPS
• Status: Completed
• Phase: N/A
• First received: December 29, 2011
• Last updated: May 6, 2015
• Start date: November 2011
• Est. completion date: January 2014

Study information

• Verified date: May 2015
• Source: Preventive Oncology International, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics CommitteeUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to develop and implement a community based preventive healthcare model using cervical cancer screening as the target medical intervention.

The investigators will first conduct 2 pilot studies to refine their preventive healthcare model based on the principles of community based participatory research (1000 participants). The investigators will then apply the model to screen 9000 women for cervical cancer over a period of 7-9 days. This 10,000 patient trial will explore the ability of a community to conduct their own screening program to identify who needs medical intervention based on self-collection and centralized high-throughput low cost human papillomavirus (HPV) testing.

Description:

Screening and prevention programs in general, throughout the world, suffer from major cost constraints, poor participation, lost to follow-up, and concerns about sustainability.

Over the past 15 years the investigators have been studying self-collection as a way to reach the medically underserved for cervical cancer screening. In a recent 10,000 patient randomized clinical trial they demonstrated that a self-collected sample is equivalent in accuracy to a physician obtained endocervical specimen and can be done less expensively and with higher throughput than all current and proposed accurate testing modalities.

With the majority of the worlds' medically underserved now living in middle income countries, it is no longer necessary to think small, slow, and simple, with poor quality control. It is totally achievable with self-collection to have centralized, high-throughput, low cost per case processing, and to reach millions of women in a short period of time. Again, these concepts need not be restricted to the medically underserved, but the clarity of this paradigm is a realistic solution for a critical developing world healthcare problem. In addition, we now have solid media specimen transport cards, thereby avoiding the logistics of dealing with personal use of alcohol-based liquids, concerns about exposure temperature, and ease of transportation. Using PCR-based technologies in a self-collection algorithm has the ability to not only make the testing highly sensitive, but help to address another key issue and that is how to manage the positives. In the investigators' proposed centralized model, since the primary output of the testing provides genotyping a reasonable option for tailoring the management of the positives would exist.

Now the need is to focus on developing the models that will enable them to efficiently place the existing technologies next to the women who need them the most. Developing community based systems that remove the identification of who is abnormal from the medical model, will markedly affect the cost of preventive healthcare. In addition with community involvement in the design of the program, it is expected that their participation in the "campaigns" and follow-up will be significantly improved. Sustainability also becomes a simpler problem because of the "campaign" or "event" type model (possibly once/year, or per every 5-10years). The investigators believe that the patient recruitment and loss to follow up observed in screening programs conducted in the developing world, have their roots in asking large numbers of patients, who are not presently ill, or symptomatic, to travel long distances and interrupt their daily life. The investigators believe that a much more effective program can be designed by the community, and using a self-collection model will ensure greater recruitment and participation, minimizing loss to follow up. This project CHICAPS is designed to further develop the community based screening model and in addition randomize treatment options to explore a technology more suited to rural environments

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8382
• Est. completion date: January 2014
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 35 Years to 59 Years

Eligibility

Inclusion Criteria:

Inclusion Criteria

1. Non pregnant women 35-59 years of age.

2. No hysterectomy

3. No prior pelvic radiation.

4. Willing to sign consent form

Exclusion Criteria:

1. Males

2. Women younger than 35 years old and older than 59 years old.

3. Pregnant women.

4. Patients with known history of hysterectomy or radiation for a pelvic cancer.

5. Refusal to participate

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Carcinoma in Situ
• Cervical Cancer
• Cervical Dysplasia
• Cervical Intraepithelial Neoplasia
• Cervical Neoplasm
• Human Papillomavirus
• Uterine Cervical Dysplasia
• Uterine Cervical Neoplasms

Intervention

Procedure:
• cryotherapy
cryotherapy treatment of the uterine cervix
• Colposcopy
Colposcopy, biopsy and LEEP based on the pathology results

Locations

Country	Name	City	State
China	HeShan Public Health Department	Jiangmen Municipal City	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Preventive Oncology International, Inc.	Peking University Shenzhen Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The investigators will determine the percentage of the population in the target area that are reached by the screening protocol.	Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months.	Ongoing for up to 36 months	No
Primary	The investigators will determine the percentage of HPV screen positive women who return for evaluation and treatment.	Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months	Ongoing for up to 36 months	No
Secondary	The investigators will compare women treated in the standard of care arm and the experimental arm (VIA and cryotherapy) to determine the percentage of high grade disease at the 6 month follow-up and 2 year follow-up.	Pilot study will take up to 8 months. The community application will be complete approximately 5 months later and all follow up and data analysis will be complete in 36 months	Ongoing for up to 36 months	No